NCT00330460View on ClinicalTrials.gov

A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.

PHASE3CompletedINTERVENTIONAL
Enrollment

1,189

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

January 31, 2008

Conditions
OsteoporosisOsteopenia
Interventions
DRUG

Alendronate

ALN; 70 mg; oral; once weekly

DRUG

Denosumab

60 mg; SC; every 6 months

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00330460 - A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density. | Biotech Hunter | Biotech Hunter